Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Expectations By $1.87 EPS

Monopar Therapeutics (NASDAQ:MNPR) announced its earnings results on Monday. The company reported ($2.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($1.87), Zacks reports.

Monopar Therapeutics Price Performance

NASDAQ:MNPR traded down $2.98 during mid-day trading on Tuesday, reaching $33.43. The stock had a trading volume of 36,875 shares, compared to its average volume of 357,146. Monopar Therapeutics has a 12 month low of $1.72 and a 12 month high of $54.30. The stock has a market capitalization of $203.99 million, a PE ratio of -16.97 and a beta of 1.18. The stock has a 50-day simple moving average of $38.48 and a two-hundred day simple moving average of $24.33.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on MNPR shares. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Monopar Therapeutics in a research report on Tuesday. Piper Sandler reiterated an “overweight” rating and set a $76.00 target price on shares of Monopar Therapeutics in a research report on Wednesday, March 19th.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.